By Sabela Ojea

 

GlaxoSmithKline PLC said Tuesday that its Apretude drug, which reduces the risk of HIV acquisition, has been approved by the U.S. Food and Drug Administration.

The British pharma major said that Apretude was developed by ViiV Healthcare, the specialist HIV company majority owned by GSK.

"Apretude is the first and only pre-exposure prophylaxis option to reduce the risk of sexually acquired HIV," the FTSE 100 listed company said.

The drug was approved for use by adults and adolescents weighing at least 35 kilograms, the company said.

"With Apretude, people can reduce the risk of acquiring HIV with as few as six injections a year," said Deborah Waterhouse, Chief Executive of ViiV Healthcare.

 

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

 

(END) Dow Jones Newswires

December 21, 2021 02:33 ET (07:33 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Gsk Charts.